Shenzhen Lirui Pharmaceutical Technology

Shenzhen Lirui Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Shenzhen, China, specializing in the discovery and development of innovative small molecule drugs. The company primarily focuses on metabolic diseases, including obesity, type 2 diabetes, and metabolic-associated steatohepatitis (MASH). Its lead programs, LR07 and LR08, are oral small molecule agonists targeting the GLP-1 and GIP receptors, designed to offer improved patient compliance over traditional injectable therapies. Lirui leverages its internal research platform to develop differentiated candidates with optimized pharmacological profiles. The company is actively advancing its pipeline through clinical trials in China and aims to address the growing global burden of metabolic disorders. Lirui's approach combines deep expertise in medicinal chemistry with a focus on high-value, clinically validated targets.